These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35818071)

  • 1. Implementation of buprenorphine services in NYC syringe services programs: a qualitative process evaluation.
    Jakubowski A; Rath C; Harocopos A; Wright M; Welch A; Kattan J; Navos Behrends C; Lopez-Castro T; Fox AD
    Harm Reduct J; 2022 Jul; 19(1):75. PubMed ID: 35818071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "We'll be able to take care of ourselves" - A qualitative study of client attitudes toward implementing buprenorphine treatment at syringe services programs.
    Frost T; Deutsch S; Brown S; Lemien E; Cunningham CO; Fox AD
    Subst Abus; 2021; 42(4):983-989. PubMed ID: 33759722
    [No Abstract]   [Full Text] [Related]  

  • 3. The effects of COVID-19 on New York State's Drug User Health Hubs and syringe service programs: a qualitative study.
    Ude M; Behrends CN; Kelly S; Schackman BR; Clear A; Goldberg R; Gelberg K; Kapadia SN
    Harm Reduct J; 2023 Feb; 20(1):12. PubMed ID: 36732773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine implementation at syringe service programs following waiver of the Ryan Haight Act in the United States.
    Lambdin BH; Bluthenthal RN; Tookes HE; Wenger L; Morris T; LaKosky P; Kral AH
    Drug Alcohol Depend; 2022 Aug; 237():109504. PubMed ID: 35688052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Onsite buprenorphine inductions at harm reduction agencies to increase treatment engagement and reduce HIV risk: Design and rationale.
    Perez-Correa A; Abbas B; Riback L; Ghiroli M; Norton B; Murphy S; Jakubowski A; Hayes BT; Cunningham CO; Fox AD
    Contemp Clin Trials; 2022 Mar; 114():106674. PubMed ID: 34990854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Referral to and engagement in substance use disorder treatment within opioid intervention courts in New York: a qualitative study of implementation barriers and facilitators.
    O'Grady MA; Elkington KS; Robson G; Achebe IY; Williams AR; Cohall AT; Cohall R; Christofferson M; Garcia A; Ramsey KS; Lincourt P; Tross S
    Subst Abuse Treat Prev Policy; 2024 Jan; 19(1):12. PubMed ID: 38287329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature.
    Jakubowski A; Fowler S; Fox AD
    Addict Sci Clin Pract; 2023 Jun; 18(1):40. PubMed ID: 37301953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mobile service delivery in response to the opioid epidemic in Philadelphia.
    Stewart RE; Christian HP; Cardamone NC; Abrams C; Drob C; Mandell DS; Metzger D; Lowenstein M
    Addict Sci Clin Pract; 2023 Nov; 18(1):71. PubMed ID: 38031174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs.
    Adams JW; Savinkina A; Fox A; Behrends CN; Madushani RWMA; Wang J; Chatterjee A; Walley AY; Barocas JA; Linas BP
    Addiction; 2022 Oct; 117(10):2635-2648. PubMed ID: 35315148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of buprenorphine initiation and warm handoff protocols in emergency departments: A qualitative study of Pennsylvania hospitals.
    Patel E; Solomon K; Saleem H; Saloner B; Pugh T; Hulsey E; Leontsini E
    J Subst Abuse Treat; 2022 May; 136():108658. PubMed ID: 34774397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Experience of Implementing a Low-Threshold Buprenorphine Treatment Program in a Non-Urban Medical Practice.
    Kapadia SN; Griffin JL; Waldman J; Ziebarth NR; Schackman BR; Behrends CN
    Subst Use Misuse; 2022; 57(2):308-315. PubMed ID: 34889691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.
    Burke KN; Krawczyk N; Li Y; Byrne L; Desai IK; Bandara S; Feder KA
    J Subst Use Addict Treat; 2024 Jul; 162():209351. PubMed ID: 38499248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Harm Reduction Approach to Treating Opioid Use Disorder in an Independent Primary Care Practice: a Qualitative Study.
    Kapadia SN; Griffin JL; Waldman J; Ziebarth NR; Schackman BR; Behrends CN
    J Gen Intern Med; 2021 Jul; 36(7):1898-1905. PubMed ID: 33469774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Syringe services programs: An examination of legal, policy, and funding barriers in the midst of the evolving opioid crisis in the U.S.
    Jones CM
    Int J Drug Policy; 2019 Aug; 70():22-32. PubMed ID: 31059965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of a rural emergency department-initiated buprenorphine program in the mountain west: a study protocol.
    Seliski N; Madsen T; Eley S; Colosimo J; Engar T; Gordon A; Barnett C; Humiston G; Morsillo T; Stolebarger L; Smid MC; Cochran G
    Addict Sci Clin Pract; 2024 Sep; 19(1):63. PubMed ID: 39228007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Availability of telehealth-based services at syringe services programs under the COVID-19 Public Health Emergency.
    Bartholomew TS; Tookes HE; Chueng TA; Bluthenthal RN; Wenger LD; Kral AH; Lambdin BH
    Harm Reduct J; 2023 Sep; 20(1):122. PubMed ID: 37660029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
    Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
    Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs of opioid overdose education and naloxone distribution in New York City.
    Behrends CN; Gutkind S; Winkelstein E; Wright M; Dolatshahi J; Welch A; Paone D; Kunins HV; Schackman BR
    Subst Abus; 2022; 43(1):692-698. PubMed ID: 34666633
    [No Abstract]   [Full Text] [Related]  

  • 19. Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives.
    Aronowitz SV; Engel-Rebitzer E; Dolan A; Oyekanmi K; Mandell D; Meisel Z; South E; Lowenstein M
    Harm Reduct J; 2021 Nov; 18(1):119. PubMed ID: 34823538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing harm reduction and overdose response services between community-based and public health department syringe service programmes using a national cross-sectional survey.
    Ray BR; Humphrey JL; Patel SV; Akiba CF; Bluthenthal RN; Tookes H; LaKosky PA; Wenger LD; Kral AH; Lambdin BH
    Lancet Reg Health Am; 2024 Jun; 34():100757. PubMed ID: 38745887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.